Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMAvax-EGF in Advanced NSCLC
NCT00516685Phase 3Terminated
- Sponsor
- Bioven
- Start
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of cimavax egf in non-small cell lung cancer (NSCLC), sponsored by Bioven. Started Jul 2007; status: terminated.
02
Drugs
cimavax egf
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00516685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516685.